Glaukos (NYSE:GKOS) PT Raised to $110.00 at JPMorgan Chase & Co.

Glaukos (NYSE:GKOS) had its price objective upped by stock analysts at JPMorgan Chase & Co. from $108.00 to $110.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 3.18% from the company’s previous close.

Other research analysts have also issued research reports about the company. Citigroup increased their price target on Glaukos from $107.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, March 25th. Truist Financial reaffirmed a “buy” rating and set a $125.00 price target (up previously from $120.00) on shares of Glaukos in a research report on Thursday. Wells Fargo & Company upped their price objective on Glaukos from $103.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday. StockNews.com lowered shares of Glaukos from a “hold” rating to a “sell” rating in a report on Tuesday, February 27th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $110.00 price objective on shares of Glaukos in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.40.

Glaukos Stock Performance

NYSE:GKOS traded up $7.70 during mid-day trading on Thursday, reaching $106.61. The stock had a trading volume of 318,033 shares, compared to its average volume of 648,743. Glaukos has a twelve month low of $45.47 and a twelve month high of $108.22. The business has a 50 day simple moving average of $92.71 and a 200 day simple moving average of $82.43. The firm has a market capitalization of $5.35 billion, a price-to-earnings ratio of -38.20 and a beta of 1.08. The company has a debt-to-equity ratio of 0.77, a quick ratio of 4.78 and a current ratio of 5.34.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.12). The company had revenue of $85.60 million for the quarter, compared to analyst estimates of $79.60 million. Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The company’s revenue for the quarter was up 15.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.59) earnings per share. On average, analysts expect that Glaukos will post -2.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Glaukos

In related news, CFO Alex R. Thurman sold 474 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $90.37, for a total value of $42,835.38. Following the completion of the transaction, the chief financial officer now directly owns 54,916 shares of the company’s stock, valued at approximately $4,962,758.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, COO Joseph E. Gilliam sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $96.07, for a total transaction of $480,350.00. Following the transaction, the chief operating officer now owns 119,802 shares in the company, valued at $11,509,378.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Alex R. Thurman sold 474 shares of Glaukos stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $90.37, for a total value of $42,835.38. Following the transaction, the chief financial officer now directly owns 54,916 shares in the company, valued at $4,962,758.92. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 232,881 shares of company stock worth $21,965,491. 6.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Glaukos

A number of institutional investors have recently bought and sold shares of GKOS. Xponance Inc. boosted its holdings in shares of Glaukos by 4.1% in the fourth quarter. Xponance Inc. now owns 2,879 shares of the medical instruments supplier’s stock worth $229,000 after buying an additional 113 shares during the period. Valeo Financial Advisors LLC grew its position in Glaukos by 1.7% during the 1st quarter. Valeo Financial Advisors LLC now owns 8,932 shares of the medical instruments supplier’s stock worth $902,000 after purchasing an additional 150 shares in the last quarter. Corient Private Wealth LLC lifted its holdings in shares of Glaukos by 0.7% in the fourth quarter. Corient Private Wealth LLC now owns 24,775 shares of the medical instruments supplier’s stock valued at $1,969,000 after purchasing an additional 163 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Glaukos by 2.1% in the third quarter. Arizona State Retirement System now owns 13,040 shares of the medical instruments supplier’s stock worth $981,000 after buying an additional 264 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Glaukos by 17.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock valued at $137,000 after buying an additional 270 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.